These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID; BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676 [No Abstract] [Full Text] [Related]
15. Update on radioligand therapy with Fuoco V; Argiroffi G; Mazzaglia S; Lorenzoni A; Guadalupi V; Franza A; Scalorbi F; Aliberti G; Chiesa C; Procopio G; Seregni E; Maccauro M Tumori; 2022 Aug; 108(4):315-325. PubMed ID: 34405748 [TBL] [Abstract][Full Text] [Related]
16. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Almuradova E; Seyyar M; Arak H; Tamer F; Kefeli U; Koca S; Sen E; Telli TA; Karatas F; Gokmen I; Turhal NS; Sakalar T; Ayhan M; Ekinci F; Hafizoglu E; Kahraman S; Kesen O; Unal C; Alan O; Celik S; Yekeduz E; Omur O; Gokmen E Int J Cancer; 2024 Feb; 154(4):692-700. PubMed ID: 37818966 [TBL] [Abstract][Full Text] [Related]
17. Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. Luining WI; Cysouw MCF; Meijer D; Hendrikse NH; Boellaard R; Vis AN; Oprea-Lager DE Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267481 [TBL] [Abstract][Full Text] [Related]
18. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer? Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965 [TBL] [Abstract][Full Text] [Related]
19. First-in-human study of Zang J; Fan X; Wang H; Liu Q; Wang J; Li H; Li F; Jacobson O; Niu G; Zhu Z; Chen X Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):148-158. PubMed ID: 30090965 [TBL] [Abstract][Full Text] [Related]
20. Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]